Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more
Market Cap & Net Worth: Shandong Lukang Pharmaceutical Co Ltd (600789)
Shandong Lukang Pharmaceutical Co Ltd (SHG:600789) has a market capitalization of $1.18 Billion (CN¥8.66 Billion) as of March 30, 2026. Listed on the SHG stock exchange, this China-based company holds position #7964 globally and #1411 in its home market, demonstrating a -6.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Lukang Pharmaceutical Co Ltd's stock price CN¥8.29 by its total outstanding shares 1045189778 (1.05 Billion).
Shandong Lukang Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Shandong Lukang Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.41 Billion to $1.18 Billion (-0.35% CAGR).
Shandong Lukang Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Lukang Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
Shandong Lukang Pharmaceutical Co Ltd's market cap is 0.22 times its annual revenue
1.05x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.45x
Shandong Lukang Pharmaceutical Co Ltd's market cap is 3.45 times its annual earnings
10.77x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.41 Billion | $2.41 Billion | $7.90 Million | 0.58x | 178.03x |
| 2016 | $1.02 Billion | $2.51 Billion | $29.10 Million | 0.41x | 35.14x |
| 2017 | $839.39 Million | $2.60 Billion | $114.24 Million | 0.32x | 7.35x |
| 2018 | $799.39 Million | $3.33 Billion | $161.39 Million | 0.24x | 4.95x |
| 2019 | $998.56 Million | $3.73 Billion | $121.25 Million | 0.27x | 8.24x |
| 2020 | $1.30 Billion | $4.21 Billion | $227.88 Million | 0.31x | 5.72x |
| 2021 | $1.05 Billion | $4.92 Billion | $89.10 Million | 0.21x | 11.78x |
| 2022 | $1.03 Billion | $5.62 Billion | $138.01 Million | 0.18x | 7.43x |
| 2023 | $1.02 Billion | $6.15 Billion | $246.17 Million | 0.17x | 4.13x |
| 2024 | $1.36 Billion | $6.23 Billion | $394.62 Million | 0.22x | 3.45x |
Competitor Companies of 600789 by Market Capitalization
Companies near Shandong Lukang Pharmaceutical Co Ltd in the global market cap rankings as of March 30, 2026.
Key companies related to Shandong Lukang Pharmaceutical Co Ltd by market ranking:
- Haleon plc (NYSE:HLN): Ranked #427 globally with a market cap of $49.87 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #428 globally with a market cap of $49.85 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #707 globally with a market cap of $28.23 Billion USD ( CN¥207.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #427 | Haleon plc | NYSE:HLN | $49.87 Billion | $9.80 |
| #428 | Zoetis Inc | NYSE:ZTS | $49.85 Billion | $113.35 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #707 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.23 Billion | CN¥55.18 |
Shandong Lukang Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shandong Lukang Pharmaceutical Co Ltd's market cap moved from $1.41 Billion to $ 1.18 Billion, with a yearly change of -0.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.18 Billion | -8.30% |
| 2025 | CN¥1.29 Billion | -5.34% |
| 2024 | CN¥1.36 Billion | +33.75% |
| 2023 | CN¥1.02 Billion | -0.84% |
| 2022 | CN¥1.03 Billion | -2.31% |
| 2021 | CN¥1.05 Billion | -19.45% |
| 2020 | CN¥1.30 Billion | +30.55% |
| 2019 | CN¥998.56 Million | +24.92% |
| 2018 | CN¥799.39 Million | -4.77% |
| 2017 | CN¥839.39 Million | -17.92% |
| 2016 | CN¥1.02 Billion | -27.27% |
| 2015 | CN¥1.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 29th, 2026 the market cap of Shandong Lukang Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Billion USD |
| MoneyControl | $1.18 Billion USD |
| MarketWatch | $1.18 Billion USD |
| marketcap.company | $1.18 Billion USD |
| Reuters | $1.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.